论文部分内容阅读
[目的]评价吉西他滨联合奈达铂治疗晚期鼻咽癌的疗效和毒副作用。[方法]64例晚期鼻咽癌患者随机分为治疗组和对照组,各32例,治疗组采用吉西他滨联合奈达铂治疗,对照组采用氟尿嘧啶联合顺铂治疗。评价两组疗效和毒副反应。[结果]治疗组:CR6例,PR20例,SD4例,PD2例,有效率81.25%;1年生存率93.75%。对照组:CR4例,PR16例,SD7例,PD5例,有效率62.50%;1年生存率81.25%。对照组消化道反应及口腔黏膜反应发生率均明显高于治疗组(P<0.05),而血小板抑制发生率治疗组明显高于对照组(P<0.05)。[结论]吉西他滨联合奈达铂一线治疗晚期鼻咽癌近期疗效较好,安全性良好。
[Objective] To evaluate the efficacy and toxicity of gemcitabine combined with nedaplatin in the treatment of advanced nasopharyngeal carcinoma. [Method] 64 patients with advanced nasopharyngeal carcinoma were randomly divided into treatment group and control group, with 32 cases each. The treatment group was treated with gemcitabine combined with nedaplatin, the control group was treated with fluorouracil combined with cisplatin. Evaluation of two groups efficacy and toxicity. [Results] The treatment group: CR6 cases, PR20 cases, SD4 cases and PD2 cases, with an effective rate of 81.25% and a one-year survival rate of 93.75%. Control group: CR4 cases, PR16 cases, SD7 cases, PD5 cases, effective rate 62.50%; 1-year survival rate was 81.25%. The incidence of digestive tract reaction and oral mucosal reaction in the control group were significantly higher than that in the treatment group (P <0.05), while the incidence of platelet inhibition in the treatment group was significantly higher than that in the control group (P <0.05). [Conclusion] Gemcitabine combined with nedaplatin first-line treatment of advanced nasopharyngeal carcinoma has good curative effect and good safety.